Dinar

Quick links to important sections

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dinar

What is Dinar? Definition and Classification as a Cephalosporin

Property Description
Active ingredient Cefdinir
Form Capsules and Oral Suspension
Pharmacological class Third-Generation Cephalosporin Antibiotic
Common use Systemic treatment of bacterial infections
Origin Semisynthetic

Dinar is a prescription-only medication that contains the active ingredient Cefdinir, which is classified as an antibiotic. Cefdinir belongs specifically to the third-generation cephalosporin group, a major class of antimicrobial agents utilized in human medicine. This designation highlights its structure and enhanced activity against a variety of bacteria.

The active compound, Cefdinir, is semisynthetic, derived from natural antibiotic compounds and chemically modified to improve its stability and broaden its spectrum of activity. Dinar is clinically recognized for its reliable efficacy against many common bacterial infections, making it a typical choice for addressing susceptible microorganisms in various tissues.

Composition, Origin, and Available Forms (Capsules and Suspension)

Dinar is a single-ingredient product, confirming that all therapeutic effects stem exclusively from the Cefdinir agent. It is supplied for oral administration in two distinct pharmaceutical preparations to maximize patient suitability.

These official forms include hard capsules and a powdered product that is mixed with water to create an oral suspension. The availability of the liquid oral suspension form is a key distinguishing factor, making the medication readily accessible for specific pediatric patients, such as children aged six months and older. This design for oral administration ensures the drug is absorbed from the gastrointestinal tract and distributed throughout the body to fight the infection.

The General Purpose: Bactericidal Action Against Bacterial Infections

The primary general purpose of Dinar is to fight illnesses caused by susceptible bacterial infections. Its fundamental mechanism is described as bactericidal activity, meaning the drug works by directly killing the invading bacteria rather than just inhibiting their growth. A comprehensive review of cephalosporins emphasizes their critical role in achieving high cure rates due to this lethal action.

This action is achieved by interfering with the integrity of the bacterial cell wall. Cefdinir's structure as a third-generation cephalosporin gives it broad-spectrum activity against various types of bacteria, helping the body overcome the underlying infectious process.

Regulatory References

  1. Cefdinir (Oral Route) Monograph

What side effects are possible with Dinar?

Possible Side Effects and Safety Information

The safety profile of Dinar (Cefdinir) is formally structured by government regulatory agencies, detailing adverse reactions by their expected frequency and the affected body systems. Adverse reactions are classified based on clinical trial data and post-marketing surveillance as documented in the FDA Prescribing Information and European Summary of Product Characteristics (SmPC).

Adverse Reaction Frequency Examples of Officially Documented Effects
Common Diarrhea, Nausea, Headache, Vaginal Moniliasis (in adult females).
Less Common to Rare Vomiting, Abdominal Pain, Rash, Maculopapular rash, Leukopenia, Jaundice.

Adverse effects are grouped into System-Organ Classes (SOCs), with the most frequently affected categories being Gastrointestinal Disorders and Skin and Subcutaneous Tissue Disorders. Other SOCs include the Blood and Lymphatic System, Immune System, and Hepatobiliary Disorders.

Serious Adverse Reactions and Key Safety Constraints

Regulatory documents list several Serious Adverse Reactions (SARs), which are rare but clinically significant. These include severe hypersensitivity events such as Anaphylaxis and severe dermatological conditions like Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN). The medication may also be associated with Pseudomembranous Colitis (Clostridioides difficile-associated diarrhea), which can occur during or even after treatment is finished.

The medicine is contraindicated in individuals with a known hypersensitivity to the cephalosporin class of antibiotics. Due to the way Cefdinir is cleared from the body, specific population safety notes require caution for older adults and mandatory dose adjustment for patients with significant renal impairment, as systemic exposure to the drug is increased in these groups.

Overdose and Emergency Response

Overdose Scope: Official Regulatory Guidance for Dinar (Cefdinir)

Scope Element Official Regulatory Statement
Documented Overdose Presentations Overdose symptoms are described by analogy to the documented toxicity profile of related beta-lactam antibiotics, which may include nausea, vomiting, epigastric distress, and diarrhea.
Physiological Systems Affected Severe Central Nervous System (CNS) effects are a documented possibility based on class-specific data, specifically the potential for convulsions (seizures).
Population-Specific Overdose Notes The official prescribing information explicitly states that specific information on cefdinir overdosage in humans is not available.

Emergency Response and Required Actions

Classification Element Official Regulatory Statement
Immediate Actions and Treatment Treatment following an overdose is generally symptomatic and supportive. There is no specific antidote known.
Supportive Procedure Hemodialysis is documented to remove cefdinir from the body, and may be used as a procedural step during supportive management.
When Immediate Medical Help is Required Seek emergency medical attention and contact a Poison Control center immediately. Urgent intervention is required if the individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Connection to the Overall Overdose Profile: The regulatory documents establish the overdose profile by referencing potential manifestations common to its antibiotic class, such as gastrointestinal upset and severe neurological events. This documented risk profile directly mandates immediate contact with emergency services, particularly when life-threatening symptoms are present. The profile is further defined by the documentation of hemodialysis as a specific method for drug clearance during supportive care.

Therapeutic Uses of Dinar

What Dinar Treats: Main Uses and Benefits

Dinar (Cefdinir) is commonly used to help manage symptoms related to acute or episodic changes caused by treatable conditions. The therapeutic use of Dinar is applied in clinical settings that involve acute or disruptive symptom patterns where short-term symptomatic assistance is needed to address significant discomfort.

This medication is typically prescribed for managing heightened symptoms associated with acute episodes like sinusitis, pharyngitis, tonsillitis, and middle ear infection (acute otitis media), as well as specific types of pneumonia and uncomplicated skin and soft tissue infections. Dinar helps address symptom clusters that may become intense or disruptive, including severe pain, pressure, localized swelling, and fever.

Dinar's function is to provide support that helps ease the overall symptom burden and assists with maintaining functional stability during the illness.

“Dinar supports the patient during difficult episodes by easing distress and contributing to easing the overall symptom load.”

It is further used across domains where additional symptomatic support is needed for managing symptoms related to the lower respiratory tract, relevant in conditions involving inflammatory or irritative processes like acute exacerbations of chronic bronchitis.


Quick Fact: Support for Managing Infection-Related Pain (It is commonly used to help manage symptoms related to physical discomfort, such as earaches, sore throats, and localized skin pain.)

Regulatory References

  1. Official FDA Labeling via DailyMed

Eligibility and Restrictions for Use

Who Can and Cannot Use Dinar?

This section outlines the official population eligibility for Dinar (Cefdinir), based strictly on regulatory documents.


Contraindications and Absolute Non-Eligibility

Dinar is contraindicated in patients with a known allergy or hypersensitivity to the active ingredient, Cefdinir, or to the entire cephalosporin class of antibiotics. [Table of eligibility classification is not included due to word count limit. The information is integrated into the text.]

Age-Related and Conditional Eligibility

Eligibility is established for adults, adolescents (13 years and older), and pediatric patients from 6 months through 12 years of age. Use is not established and therefore not recommended for infants younger than 6 months.

Conditional use applies to patients with markedly compromised renal function (Creatinine Clearance < 30 mL/min), including those on hemodialysis. These patients require restricted use as determined by official labeling. Caution is also advised for individuals with a history of colitis or using the oral suspension form if they are diabetic (due to sucrose content).

Pregnancy and Lactation Status

Use during pregnancy is permitted only if clearly needed. Use while lactating is generally considered acceptable by regulators.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documentation for Dinar (Cefdinir) identifies specific pharmacokinetic and pharmacodynamic interaction patterns, primarily categorized by altered absorption or modified clearance, with no combinations classified as absolute contraindications.

Documented Pharmacokinetic Interactions

Interacting Substance Official Interaction Pattern Regulatory Restriction
Antacids (Magnesium/Aluminum) Reduced Cefdinir Absorption (Pharmacokinetic) Must be separated by at least 3 hours
Iron Supplements/Products Reduced Cefdinir Absorption (Pharmacokinetic) Must be separated by at least 3 hours
Probenecid Increased Cefdinir Plasma Exposure by inhibiting renal clearance Use with caution (Monitoring advised)

Documented Pharmacodynamic Interactions

Co-administration with oral anticoagulants (such as Warfarin) is officially documented to have a pharmacodynamic effect that may result in an alteration of the International Normalized Ratio (INR). This potential effect requires monitoring. No formal interaction is documented with alcohol, herbal products, or other common supplements in the official prescribing information. All interaction restrictions are based strictly on regulatory labeling.

Mechanism of Action

Covalent Inhibition of Bacterial Cell Wall Assembly

Dinar's mechanism involves the active ingredient Cefdinir acting as an irreversible inhibitor of Penicillin-Binding Proteins (PBPs), which are bacterial enzymes essential for building the cell wall. Cefdinir forms a stable, covalent bond with a key residue in the active site of these PBPs, preventing the crucial cross-linking of peptidoglycan chains, thus halting the completion of the cell's structural integrity.


Triggering Osmotic Lysis and Bactericidal Action

This structural deficiency leads to a catastrophic physiological consequence: the weakened bacterial cell wall can no longer counteract the cell's high internal osmotic pressure. The cell rapidly swells and ruptures (lysis), a direct action resulting in a bactericidal effect. This targeted mechanism results in the death and lysis of susceptible cells.


Mechanisms of Reduced Effectiveness

The mechanism is biologically limited when bacteria develop countermeasures. These include the production of beta-lactamase enzymes that chemically neutralize the active ingredient before it can reach the PBPs, or the modification of PBP targets which reduces Cefdinir's binding affinity. These resistance mechanisms interfere with the drug's core action, resulting in inadequate PBP inhibition to consistently cause cell lysis.

Dosage and Administration Information

How to Use Dinar (Cefdinir) - Administration Guidelines

Administration of Dinar is based on clinical guidelines focusing on the correct dose, frequency, and relationship to meals. The medication is prescribed for oral administration only and is available as a 300 mg capsule or as a powder for oral suspension in two concentrations: 125 mg/5 mL and 250 mg/5 mL.


Standard Dosing and Frequency

Patient Group Total Daily Dose Frequency Pattern Typical Duration
Adults & Adolescents 600 mg Once or Twice Daily 5 to 10 days
Pediatric (6 months-12 yrs) 14 mg/kg (Max 600 mg) Once or Twice Daily 5 to 10 days

The standard adult daily dose of 600 mg is typically given as 300 mg every 12 hours (twice daily), although a single 600 mg dose once daily is an option for certain infections like pharyngitis. The full course, which is commonly 5 or 10 days, must be completed.


Administration Context and Adjustments

Dinar can be taken without regard to meals (with or without food). If the liquid suspension is used, the reconstituted product must be shaken well before each dose is measured and administered.

A critical procedural condition is the timing relative to certain supplements: Dinar must be administered at least 2 hours before or 2 hours after taking antacids or products containing iron (such as some multivitamins), as these substances can reduce the absorption of Cefdinir. For patients with severely impaired kidney function (creatinine clearance <30 mL/min), a dose reduction to 300 mg once daily is required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dinar (Cefdinir)


Evidence for Common Respiratory Tract Infections

The research explored Dinar's study for common respiratory conditions primarily relies on short-term, randomized, controlled trials (RCTs). These studies were designed to explore the use of Dinar in conditions characterized by periods of heightened symptoms, such as Acute Bacterial Exacerbations of Chronic Bronchitis (ABECB), certain forms of Community-Acquired Pneumonia (CAP), and Acute Maxillary Sinusitis.

In these trials, researchers examined patient-reported outcomes describing perceived discomfort, along with measurements of clinical response and the rate at which the targeted bacteria was monitored for eradication from the body. Studies focusing on CAP were primarily evaluated in patients with mild-to-moderate infections, leaving limited information for more severe cases.


Evidence for Pharyngitis, Tonsillitis, and Middle Ear Infection

Dinar was studied for common ear and throat issues, including Pharyngitis / Tonsillitis and Acute Otitis Media (AOM), mainly through comparative RCTs. The research was evaluated in broad populations, including pediatric patients starting at six months of age, adolescents, and adults.

For Pharyngitis/Tonsillitis, studies often report patterns related to bacteriological success rates and outcomes related to physical discomfort. For AOM, subgroup findings were mixed. Evidence suggests that clinical response measurements in children younger than 24 months or those with recurrent AOM demonstrate variability in the research. Sample sizes were modest in some AOM trials that attempted to confirm microbiological status through invasive means, meaning findings are generally based on clinical diagnosis rather than lab confirmation.


Evidence Landscape and Research Gaps

Research supporting the study of Dinar for conditions like Urinary Tract Infections (UTIs) often arises from retrospective evaluations and observational comparative studies, not large-scale RCTs. Consequently, the evidence quality varies across studies for these indications, and certainty remains low.

A consistent finding across all research is that follow-up durations were limited. There is limited information for long-term outcomes regarding the durability of the clinical response or the potential for symptom recurrence over extended periods. Data for other special populations, such as the elderly or those with certain underlying co-morbidities, remain insufficient in the primary controlled trials.

Key Studies & References

  1. Cefdinir Capsule and Oral Suspension Official FDA Labeling via DailyMed
  2. A meta-analysis of cefdinir versus amoxicillin/clavulanate for the treatment of acute otitis media
  3. IDSA Clinical Practice Guideline for Acute Bacterial Rhinosinusitis in Children and Adults

Frequently Asked Questions (FAQ)

Common questions about Dinar (FAQ)


Q: What happens if I stop taking Dinar suddenly?

Official administration instructions emphasize that the full prescribed course of the drug must be completed for the successful treatment of the bacterial infection. Regulatory sources do not detail specific outcomes of sudden cessation, but completing the full course is defined as a required procedural condition.


Q: Can Dinar cause long-term problems or side effects?

Regulatory documents and supporting research indicate that studies exploring the drug's use had limited follow-up durations. Consequently, there is limited information in the available clinical trials regarding long-term outcomes or the durability of the clinical response over extended periods.


Q: What are the most common side effects people report with Dinar?

According to official prescribing information and clinical trial data, the most frequently reported common effects are diarrhea, nausea, headache, and a fungal infection called vaginal moniliasis (in adult females).


Q: What is the earliest age someone can typically be prescribed Dinar?

Official regulatory documents indicate that the use of Dinar is established for pediatric patients starting from 6 months of age. Use is not established for infants younger than 6 months.


Q: Can Dinar interfere with birth control pills?

Official information indicates that the active ingredient in Dinar, Cefdinir, may be associated with reduced effectiveness of certain oral contraceptives containing ethinyl estradiol. This potential interaction may increase the risk of breakthrough bleeding or unintended pregnancy.


Q: Why does Dinar sometimes cause dizziness?

Dizziness is not listed as a common effect in clinical trials, but regulatory safety reports list it as a less frequent or post-marketing adverse reaction. Official documentation encourages patients to be aware of how they respond to the medication.


Q: Does Dinar contain any ingredients I should be aware of, like lactose or gluten?

Official documentation lists several inactive ingredients, such as gelatin and magnesium stearate, in the capsule form. Specific common inactive ingredients, such as lactose or gluten, are not listed in the general regulatory information for the product's composition.


Q: How quickly does Dinar leave your system?

Pharmacokinetic information in the official documentation indicates the drug is cleared from the body primarily by the kidneys. The mean elimination half-life is officially reported as approximately 1.7 hours.


Q: Is the maximum recommended use duration for Dinar specified anywhere?

Official dosing guidelines and regulatory documents list the maximum typical treatment duration as 10 days for both adult and pediatric patient groups, although shorter courses (like 5 days) may be prescribed.


Q: Is Dinar the same kind of medicine as [similar drug name]? What's the difference?

Dinar is classified as a third-generation cephalosporin antibiotic. This classification refers to its specific chemical structure and defined activity profile compared to other drug classes or earlier generations of antibiotics, as defined in official pharmacological literature.


Q: Does Dinar have a generic version available?

Yes, official sources confirm that the active ingredient, Cefdinir, has been approved by the FDA for generic versions. These generic forms are available as both capsules and an oral suspension.


Q: How long does it usually take to notice an effect from Dinar?

Official pharmacokinetic information indicates that the maximal concentration of the drug in the blood typically occurs 2 to 4 hours after the dose is taken. Clinical trials describe outcomes in terms of 'clinical response,' which is a measurement of improvement.


Q: Is Dinar known to be habit-forming or addictive?

No. Official drug classification documents state that Dinar (Cefdinir) is not classified as a controlled substance under federal regulation.


Q: Are there any herbal remedies that interact with Dinar?

Official prescribing information does not document any formal interaction between Dinar and herbal products. It is standard practice for patients to inform their healthcare provider of all supplements being used.


Q: Does Dinar affect blood pressure or heart rate?

Official adverse event reporting lists tachycardia (an increased heart rate) as an uncommon or post-marketing adverse event reported with Dinar.


Q: What are the signs of an allergic reaction to Dinar?

Serious allergic reactions (such as Anaphylaxis) are described by regulatory bodies. Signs can include hives, rash, difficulty breathing, swelling of the face or throat, or severe skin reactions like blistering or peeling skin.


Q: Is it necessary to have a certain medical test before starting Dinar?

Official documents require that patients with significantly compromised kidney function (Creatinine Clearance <30 mL/min) must have their dosage adjusted. This procedural requirement implies that some form of renal function assessment may be necessary prior to prescribing in certain patient groups.


Q: Does Dinar only treat the symptoms or does it address the underlying issue?

Dinar is officially described as having bactericidal activity. This means its fundamental mechanism is to directly kill the susceptible bacteria that are causing the underlying infection, rather than simply suppressing the symptoms.


Q: Does Dinar affect driving or operating machinery?

Official reports list effects such as dizziness and headache as common or less common side effects. Patients are generally encouraged to be aware of how they react to the medication before engaging in activities that require mental alertness, such as driving or operating machinery.


Q: Can Dinar change my sleep patterns?

Official post-marketing surveillance reports list psychiatric/CNS events such as somnolence (drowsiness) and insomnia (difficulty sleeping), suggesting a possible but uncommon effect on sleep patterns.


Q: How long do most people stay on Dinar?

Official dosing guidelines list the typical duration of use for both adult and pediatric patients as either 5 days or 10 days, depending on the type of infection being treated.


Q: What is the general success rate of Dinar in studies?

Clinical trial results reported in official documents summarize outcomes using measures like clinical response rates and bacteriological eradication rates. These rates vary based on the specific infection being treated and the population studied.


Q: Does Dinar have any known mood-related side effects?

Official post-marketing surveillance reports list psychiatric/mood-related events, including abnormal thinking, agitation, and nervousness, as having been reported, though these are not common effects.


Q: How does Dinar compare to older drugs for the same condition, based on official information?

Dinar is classified as a third-generation cephalosporin. This classification, defined in official literature, refers to its chemical structure and its defined position in the drug class hierarchy compared to earlier-generation cephalosporins.


Q: Is Dinar a controlled substance?

No. Official drug classification documents state that Dinar (Cefdinir) is not classified as a controlled substance under federal regulation.


Q: Why is the dosage sometimes adjusted after I start Dinar?

Official dosing guidelines require a dose adjustment to a lower daily amount for patients who are found to have significantly compromised kidney function (creatinine clearance less than 30 mL/min).

How should Dinar be stored and disposed of?

Dinar (nitroglycerin sublingual tablets) must be stored properly to maintain its potency.

Storage Guidelines

  • Keep the tablets in the original glass bottle with the cap tightly screwed on after each use.
  • Store at controlled room temperature (20°C to 25°C or 68°F to 77°F), away from excess heat, moisture, and direct light.
  • Do not store in the bathroom or keep in a car, where temperatures can fluctuate severely.
  • Keep out of the sight and reach of children and pets.
  • Discard any unused portion after the expiration date on the package, or generally no longer than 3–5 months after the bottle is first opened, unless otherwise directed by your pharmacist.

Disposal Instructions

  • Do not flush unused medication down the toilet or pour into a drain unless instructed to do so by a healthcare professional or an official FDA list.
  • The preferred method for disposal is through a local drug take-back program or medication disposal event, which may be available at certain pharmacies or law enforcement locations.
  • If a take-back option is unavailable, you may dispose of the unused medicine in household trash by mixing it with an unappealing substance (e.g., used coffee grounds or dirt), placing the mixture in a sealed bag or container, and then discarding it in the trash.
  • Before discarding the packaging, scratch out all personal information on the prescription label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dinar found in:

A-Z Index: